Sun Pharma to Acquire Organon in $11.75B Deal

India-based Sun Pharmaceutical Industries Ltd. has agreed to acquire Organon & Co. in an all-cash transaction valued at $11.75 billion. 

Under the terms, Sun Pharma will purchase all outstanding Organon shares for $14 each. The deal is expected to close in early 2027, subject to regulatory approvals and shareholder consent. 

The acquisition is set to expand Sun Pharma’s global footprint, particularly in women’s health and biosimilars, while supporting its broader strategy to grow its innovative and branded medicines portfolio. Organon, which was spun off from Merck & Co. in 2021, markets more than 70 products across women’s health and general medicines in around 140 countries. 

The combined business is expected to generate approximately $12.4 billion in revenue, positioning it among the top 25 pharmaceutical companies globally and strengthening its presence in the women’s health segment. 

The transaction is likely to face standard regulatory and shareholder scrutiny as it progresses toward completion.